Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only, and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Beijing Chunlizhengda Medical Instruments Co., Ltd.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liabilities)

(Stock Code: 1858)

EXTENSION OF THE VALIDITY PERIOD OF THE RESOLUTION CONCERNING THE A SHARE OFFERING AND THE AUTHORISATION CONCERNING THE A SHARE OFFERING

References are made to the announcements of the Company dated 3 November 2015, 22 April 2020 and 5 June 2020 (the "Announcements") and the circular of the Company dated 24 July 2020 (the "Circular") in relation to, among others, the resolution concerning the A Share Offering (the "Resolution concerning the A Share Offering") and the proposal on granting authorization to the Board and its authorized representatives to fully handle the specific matters in relation to the A Share Offering (the "Authorization concerning the A Share Offering"). Unless otherwise defined, the terms used in this announcement shall have the same meanings as those defined in the Announcements and the Circular.

Proposed extension of the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering

The Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering were approved at the EGM, the Domestic Shareholders' Class Meeting and the H Shareholders' Class Meeting convened on 10 August 2020 by the Company. The validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering were 12 months from the date on which they were considered and approved at the EGM, the Domestic Shareholders' Class Meeting and the H Shareholders' Class Meeting. Given that the A Share Offering is still in progress and the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering will expire on 9 August 2021, the Board proposes to extend the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering for 12 months from the next day immediately after the expiration of validity period (i.e., ended on 9 August 2022) for the purposes of ensuring the on-going proceeding of the A Share Offering.

^{*} For identification purpose only

The above proposed resolution relating to the extension of the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering will be submitted by way of special resolution at the general meeting, the domestic shares class meeting and the H shares class meeting of the Company for consideration and approval. A circular containing, among others, the details of above resolution will be despatched to the Shareholders in due course.

Save for the abovementioned proposed extension of the validity period for the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering as disclosed in this announcement, all other terms of the A Share Offering as set out in the Circular will remain unchanged.

As the A Share Offering is subject to approval of CSRC, relevant stock exchange in the PRC and other relevant regulatory authorities may or may not proceed, Shareholders and investors are reminded to exercise caution when dealing in the H Shares of the Company. The Company will make further announcements on any material updates and developments in relation to the A Share Offering in accordance with the Listing Rules and other applicable laws and regulations.

By Order of the Board

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

SHI Chunbao

Chairman

Beijing, the PRC, 7 July 2021

As at the date of this announcement, the executive directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive director of the Company is Mr. Wang Xin; and the independent non-executive directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.